GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » iRhythm Technologies Inc (LTS:0A7L) » Definitions » Long-Term Capital Lease Obligation

iRhythm Technologies (LTS:0A7L) Long-Term Capital Lease Obligation : $77.6 Mil (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is iRhythm Technologies Long-Term Capital Lease Obligation?

iRhythm Technologies's Long-Term Capital Lease Obligation for the quarter that ended in Mar. 2024 was $77.6 Mil.

iRhythm Technologies's quarterly Long-Term Capital Lease Obligation declined from Sep. 2023 ($81.7 Mil) to Dec. 2023 ($79.7 Mil) and declined from Dec. 2023 ($79.7 Mil) to Mar. 2024 ($77.6 Mil).

iRhythm Technologies's annual Long-Term Capital Lease Obligation declined from Dec. 2021 ($85.2 Mil) to Dec. 2022 ($83.1 Mil) and declined from Dec. 2022 ($83.1 Mil) to Dec. 2023 ($79.7 Mil).


iRhythm Technologies Long-Term Capital Lease Obligation Historical Data

The historical data trend for iRhythm Technologies's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

iRhythm Technologies Long-Term Capital Lease Obligation Chart

iRhythm Technologies Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Long-Term Capital Lease Obligation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 85.75 81.29 85.21 83.07 79.72

iRhythm Technologies Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Long-Term Capital Lease Obligation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 82.01 80.24 81.72 79.72 77.64

iRhythm Technologies  (LTS:0A7L) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

iRhythm Technologies Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of iRhythm Technologies's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.


iRhythm Technologies (LTS:0A7L) Business Description

Traded in Other Exchanges
Address
699 8th Street, Suite 600, San Francisco, CA, USA, 94103
iRhythm Technologies Inc is a commercial-stage digital healthcare company redefining the way cardiac arrhythmias are clinically diagnosed by combining wearable biosensing technology with cloud-based data analytics and machine-learning capabilities. The company's portfolio include ambulatory cardiac monitoring services on a platform, called the Zio service, which combines an easy-to-wear and unobtrusive biosensor that can be worn for up to 14 consecutive days with powerful proprietary algorithms that distill data from millions of heartbeats into clinically actionable information. The company derived its revenue from the United States.

iRhythm Technologies (LTS:0A7L) Headlines

No Headlines